Telix Publishes ProstACT SELECT Study on TLX591-Tx
Melbourne, Australia & Indianapolis, Indiana, USA | July 22, 2026 Telix Pharmaceuticals announced the peer-reviewed publication of results from...
PSMA
Advertisement
Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
Convergent’s CONV01-α Shows Promising Activity in Post-Lu-PSMA Prostate Cancer Phase 2 Study
CAMBRIDGE, Mass., June 2, 2026 Convergent Therapeutics announced positive interim Phase 2 data from its CONVERGE-01 study evaluating CONV01-α...
Janux Therapeutics Doses First Patient in JANX014 Study
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
Advertisement
